Breaking News, Collaborations & Alliances, Trials & Filings

CRF’s TrialMax Slate Chosen for Phase III Study

The large-scale prostate cancer trial will involve up to 1000 screened patients across 75+ sites and 10+ countries

CRF Health announced that its TrialMax Slate solution has been selected by a US biotech company for a global Phase III prostate cancer study.    The large-scale trial will involve up to 1000 screened patients across 75+ sites and 10+ countries. The therapy targets an aggressive form of prostate cancer, where other treatment options have failed, involving seriously ill cancer patients.  This sponsor required an electronic clinical outcome assessments (eCOA) provider to support thei...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters